scholarly journals Low serum betaine levels as a potential biomarker for type 2 diabetes mellitus in patients with coronary artery disease

2020 ◽  
Author(s):  
Fei Guo ◽  
Xueting Qiu ◽  
Yuanting Zhu ◽  
Zhirong Tan ◽  
Dongsheng Ouyang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Density Lipoprotein ◽  
Lower Percentage ◽  
Potential Biomarker ◽  
Increased Risk ◽  
Artery Disease

Abstract Background Dietary betaine intake was reported to associate with improved metabolic profile in type 2 diabetes (T2D). However, the role of circulating betaine in coronary artery disease (CAD) patients with T2D is still unknown. This study aimed to investigate the potential role of serum betaine as a potential biomarker for T2D risk in CAD patients. Methods Total 307 subjects were enrolled with 165 CAD patients (57 with T2D and 108 without) and 142 age and sex matched controls (CON). Fasting serum betaine were detected using liquid chromatography tandem mass spectrometry. Results Serum betaine were lower in simple CAD patients compared with healthy controls, and were further decreased in CAD patients with T2D. Betaine was inversely associated with fasting glucose. Subjects in the highest betaine tertile group had lower triglycerides, total cholesterol and low-density lipoprotein as well was lower percentage of CAD and T2D. Increased betaine in CAD was independently associated with low risk of T2D. Furthermore, betaine was a potential diagnostic marker in distinguishing simple CAD from CAD with T2D. Conclusion Low levels of betaine are associated with increased risk of CAD and T2D in CAD, and could be a biomarker for predicting T2D in CAD.

scholarly journals IMMUNOLOGICAL STUDY OF CORONARY ARTERY DISEASE ASSOCIATED WITH DIABETES MELLITUS TYPE II IN IRAQI PATIENTS

2018 ◽  
Vol 11 (12) ◽  
pp. 269
Author(s):  
Mundher Jabbar Al-okhedi ◽  
Mohammed Qais Al-ani ◽  
Marrib N Rasheed
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Serum Levels ◽  
Control Group ◽  
Immunological Study ◽  
Increased Risk ◽  
Artery Disease

Objective: The objective of this study was to investigate the association between proinflammatory cytokines in special, the interleukin-6 (IL-6), and insulin-like growth factor (IGF-1) levels in coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM).Methods: This study was conducted from November 2017 to March 2018 in Anbar, Iraq. We studied a total of 90 individuals (46 men and 44 women) aged between 20 and 87 years. The samples were divided into four groups: CAD patients (n=23), T2DM patients (n=23), coronary artery disease and type 2 diabetes together in the same patient (n=23), and control group (n=21). The concentrations of IL-6 and IGF-1 were determined using a commercially available enzyme-linked immune sorbent assay.Results: The results of the present study showed that there were elevated serum levels of IL-6 and low levels of IGF-1 in all the tested groups, compared with the control. The difference was statistically significant at p<0.05. The results showed a positively correlated between IL-6 and IGF-1 in the CAD group and T2DM group, while it was a negative correlation between serum levels of IL-6 and IGF-1 in the T2DM+CAD group.Conclusion: Elevated levels serum of IL-6 predicts the development of CAD and T2DM. These data support a possible role for inflammation in diabetogenesis and complication of the cardiovascular disease. There is an inverse relationship between the levels serum of IGF-1 and increased risk of CAD and development of T2DM.

scholarly journals Role of Gut Microbiota on Cardio-Metabolic Parameters and Immunity in Coronary Artery Disease Patients with and without Type-2 Diabetes Mellitus

2017 ◽  
Vol 8 ◽  
Author(s):  
Lidia Sanchez-Alcoholado ◽  
Daniel Castellano-Castillo ◽  
Laura Jordán-Martínez ◽  
Isabel Moreno-Indias ◽  
Pilar Cardila-Cruz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Artery ◽  
Gut Microbiota ◽  
Metabolic Parameters ◽  
Artery Disease

scholarly journals The Relationship Between Adiponectin Serum Level and Coronary Artery Disease in Type 2 Diabetic Patients

2021 ◽  
Author(s):  
Zahra Mazloum Khorasani ◽  
Saeed Choobkar ◽  
Ramin Khameneh Bagheri ◽  
Mina AkbariRad ◽  
Abdollah Firoozi
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Serum Level ◽  
Demographic Data ◽  
Diabetic Patients ◽  
Type 2 Diabetics ◽  
Increased Risk ◽  
Artery Disease

Adiponectin is an adipocytokine that has a higher serum level in healthy people. In type 2 diabetes, insulin resistance, hypertension, MI, and dyslipidemia, the serum level of adiponectin is lower than 4 µg/mL. Adiponectin is proved to have a protective role against atherosclerotic changes where its low serum levels in type 2 diabetes can lead to the progression of atherosclerotic lesions. In this study, we aimed to survey the possible effects of adiponectin in the development of coronary artery disease in type 2 diabetics. Thirty diabetic cases with coronary artery disease, 30 diabetic cases without known coronary artery disease, and a group of 30 healthy volunteers, all of them were between 18-65-year-old, were entered ourstudy. We gathered demographic data by performing a physical examination followed by filling a checklist and a set of laboratory tests. All the groups were sex and age-matched (P=0.284 and P=0.163 respectively). CAD group had the lowest HBA1C (P<0.001). Both LDL and HDL were also lower in the CAD group (P<0.001). Adiponectin was also lower in the CAD group when compared to other groups (P<0.008) or when compared with only normal diabetics (P<0.002). We found a correlation between adiponectin and HDL (r=0.348, P=0.008), suggesting each unit of reduction in serum level of adiponectin could increase the chance of coronary artery disease by 38% in diabetics. In this study, we showed that the lower serum level of adiponectin is correlated with an increased risk of coronary artery disease in type 2 diabetics.

scholarly journals Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association

Circulation ◽  
2020 ◽  
Vol 141 (19) ◽  
Author(s):  
Suzanne V. Arnold ◽  
Deepak L. Bhatt ◽  
Gregory W. Barsness ◽  
Alexis L. Beatty ◽  
Prakash C. Deedwania ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Artery ◽  
Cardiovascular Outcomes ◽  
Artery Disease ◽  
Selection Of

Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a number of treatment choices for CAD. In this document, we discuss the role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in the selection of revascularization strategy. Second, although glycemic control has been recommended as a part of comprehensive risk factor management in patients with CAD, there is mounting evidence that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. In this document, we discuss the role of glycemic management (both in intensity of control and choice of medications) in cardiovascular outcomes. It is becoming clear that the cardiologist needs both to consider T2DM in cardiovascular treatment decisions and potentially to help guide the selection of glucose-lowering medications. Our statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2DM, with emphasis on the emerging evidence. Given the increasing prevalence of T2DM and the accumulating evidence of the need to consider T2DM in treatment decisions, this knowledge will become ever more important to optimize our patients’ cardiovascular outcomes.

scholarly journals Correlation between HFE gene polymorphisms and increased risk of coronary artery disease among patients with type 2 diabetes in Iran

2016 ◽  
Vol 46 ◽  
pp. 590-596 ◽  
Author(s):  
Leila SAREMI ◽  
Marzieh SAREMI ◽  
Shirin LOTFIPANAH ◽  
Saber IMANI ◽  
Junjiang FU ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Gene Polymorphisms ◽  
Hfe Gene ◽  
Increased Risk ◽  
Artery Disease

The Atherogenic Index of Plasma: A Powerful and Reliable Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes

Angiology ◽  
2021 ◽  
pp. 000331972110121
Author(s):  
Kuo Zhou ◽  
Zheng Qin ◽  
Jinfan Tian ◽  
Kongyong Cui ◽  
Yunfeng Yan ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Atherogenic Index ◽  
Atherogenic Index Of Plasma ◽  
Artery Disease ◽  
Cad Risk

We evaluated the predictive power of the atherogenic index of plasma (AIP) for coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM). A total of 3278 patients who underwent coronary angiography were consecutively enrolled, including 2052 patients with CAD and 1226 patients with T2DM but without CAD. Patients in the CAD group had higher levels of triglyceride (TG), total cholesterol, low-density lipoprotein cholesterol, AIP and a lower level of high-density lipoprotein cholesterol (HDL-C). In correlation analyses, AIP correlated positively with body mass index, log (homeostasis model assessment of insulin resistance), TG, remnant lipoprotein cholesterol, non–HDL-C, but negatively with age and HDL-C. Multivariate logistic regression analyses demonstrated that AIP was an independent risk factor for CAD in diabetic patients and was validated by multiple models. Furthermore, the ORs for CAD risk were raised with increasing AIP quartiles; ORs of AIP quartiles Q2–Q4 compared with Q1 were 1.56, 1.70, and 2.22, respectively ( Ps < .001), which suggested AIP was the lipid parameter that most strongly associated with incident CAD. In conclusion, AIP is a powerful and reliable biomarker for predicting CAD risk beyond individual lipid profiles in patients with T2DM.

Sign in / Sign up

Export Citation Format

Share Document